{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:31:06Z","timestamp":1789907466624,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15927"],"award-info":[{"award-number":["22K15927"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H04645"],"award-info":[{"award-number":["21H04645"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22KK0279"],"award-info":[{"award-number":["22KK0279"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20jk0110021"],"award-info":[{"award-number":["JP20jk0110021"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20he1122001"],"award-info":[{"award-number":["JP20he1122001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22fk0108542s0201"],"award-info":[{"award-number":["22fk0108542s0201"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jiac.2024.12.006","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T22:43:49Z","timestamp":1733438629000},"page":"102577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world experience of tixagevimab\/cilgavimab prophylaxis in Japanese patients with immunodeficiency"],"prefix":"10.1016","volume":"31","author":[{"given":"Kento","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3236-5098","authenticated-orcid":false,"given":"Dan","family":"Tomomasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-9719","authenticated-orcid":false,"given":"Yu","family":"Nakagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0826-2940","authenticated-orcid":false,"given":"Kousuke","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8124-6234","authenticated-orcid":false,"given":"Takahiro","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Isoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-9184","authenticated-orcid":false,"given":"Masatoshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Yoshifuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2890-0305","authenticated-orcid":false,"given":"Hidenori","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4622-5657","authenticated-orcid":false,"given":"Satoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Morio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kanegane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.12.006_bib1","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jiac.2024.12.006_bib3","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2024.12.006_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2024.12.006_bib5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jiac.2024.12.006_bib6","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jaci.2021.08.016","article-title":"Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity","volume":"148","author":"Delmonte","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jiac.2024.12.006_bib7","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10875-022-01231-7","article-title":"SARS-CoV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study","volume":"42","author":"Shields","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jiac.2024.12.006_bib8","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2024.12.006_bib9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiac492","article-title":"Antibody avidity maturation following recovery from infection or the booster vaccination grants breadth of SARS-CoV-2 neutralizing capacity","volume":"227","author":"Nakagama","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2024.12.006_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.02262-21","article-title":"A dual-antigen SARS-CoV-2 serological assay reflects antibody avidity","volume":"60","author":"Nakagama","year":"2022","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jiac.2024.12.006_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00986-22","article-title":"Detecting waning serological response with commercial immunoassays: 18-month longitudinal follow-up of anti-SARS-CoV-2 nucleocapsid antibodies","volume":"10","author":"Nakagama","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jiac.2024.12.006_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1208\/s12248-024-00904-y","article-title":"A short update on the use of monoclonal antibodies in COVID-19","volume":"26","author":"Vitiello","year":"2024","journal-title":"AAPS J"},{"key":"10.1016\/j.jiac.2024.12.006_bib13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41409-023-02019-y","article-title":"Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan","volume":"58","author":"Haraguchi","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jiac.2024.12.006_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12185-023-03629-4","article-title":"Prophylactic effect of tixagevimab-cilgavimab on COVID-19 infection and death in Japanese patients with B cell lymphoma","volume":"118","author":"Tatetsu","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jiac.2024.12.006_bib15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12185-023-03663-2","article-title":"Pre-exposure prophylaxis with tixagevimab\/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan","volume":"118","author":"Kawashima","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jiac.2024.12.006_bib16","unstructured":"Fact sheet for healthcare providers: EMERGENCY USE AUTHORIZATION FOR EVUSHELD\u2122 (tixagevimab co-packaged with cilgavimab). EVUSHELD (tixagevimab) injection; (cilgavimab) injection, co-packaged for intramuscular use. Original EUA authorized date: 12\/2022. U.S. Food and Drug Administration."},{"key":"10.1016\/j.jiac.2024.12.006_bib17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10875-023-01457-z","article-title":"Efficacy of tixagevimab and cilgavimab against SARS-CoV-2 infections in patients with inborn errors of immunity","volume":"43","author":"Johnson","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jiac.2024.12.006_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1249462","article-title":"SARS-CoV-2 pre-exposure prophylaxis with tixagevimab\/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience","volume":"14","author":"Pulvirenti","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jiac.2024.12.006_bib19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10875-022-01251-3","article-title":"Responses to SARS-CoV-2 vaccines of patients with common variable Immune Deficiencies and X-linked agammaglobulinemia","volume":"42","author":"Carrabba","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jiac.2024.12.006_bib20","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jaci.2022.04.002","article-title":"Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity","volume":"139","author":"Van Leeuwen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jiac.2024.12.006_bib21","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1016\/j.vaccine.2022.07.046","article-title":"Reponse to mRNA COVID-19 vaccination in three XLA patients","volume":"40","author":"Squire","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jiac.2024.12.006_bib22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10875-022-01231-7","article-title":"SARS-CoV-2 Vaccine Responses in individuals with antidoby deficiency: findings from the COV-AD Study","volume":"42","author":"Sields","year":"2022","journal-title":"J Clin Immunol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24003246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24003246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:48:39Z","timestamp":1738928919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24003246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1341321X24003246"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.12.006","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience of tixagevimab\/cilgavimab prophylaxis in Japanese patients with immunodeficiency","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102577"}}